FEMY · XBRL financial data

Femasys financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (FEMY's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	244	213*	271	221	555	582*	341	409	729	813*	425	332
Cost of goods and services sold	86	78*	89	73	191	192*	117	158	294	303*	159	142
Gross profit	158	135*	—	—	—	389*	—	—	—	510*	—	—
Research and development	2,073	2,071*	1,771	1,976	2,303	2,167*	2,968	1,414	1,382	1,813*	1,309	1,947
General and administrative	1,970	2,216*	1,503	1,612	1,531	1,681*	1,723	1,617	1,478	1,829*	1,782	1,932
Total operating expenses	4,239	4,584*	3,645	4,631	5,483	5,112*	5,685	4,103	4,089	5,133*	4,490	5,255
Operating income (loss)	(4,081)	(4,450)*	(3,463)	(4,482)	(5,118)	(4,723)*	(5,461)	(3,852)	(3,654)	(4,623)*	(4,224)	(5,066)
Interest income	92	199*	225	184	124	50*	19	17	17	48*	50	20
Interest expense	8	155*	362	388	413	440*	459	492	532	408*	177	186
Other income (expense)	—	—	—	0	0	0*	—	(260)	(26)	(196)*	—	0
Income tax expense (benefit)	0	4*	0	(2)	1	10*	(4)	0	0	5*	0	1
Net income (loss)	(3,997)	(4,410)*	(3,600)	(4,685)	(5,409)	(5,124)*	(5,897)	(4,586)	(4,195)	(3,950)*	846	(4,469)
Earnings per share, basic‡ USD per share	(5.20)	—	(3.40)	(4.20)	(4.80)	(4.40)*	(4.60)	(3.20)	(2.00)	—	0.00	(1.33)
Earnings per share, diluted‡ USD per share	(5.20)	—	(3.40)	(4.20)	(4.80)	(4.40)*	(4.60)	(3.20)	(2.00)	—	0.00	(1.33)
Weighted average shares, basic‡ thousands of shares	755	—	1,089	1,111	1,112	1,142*	1,257	1,444	2,051	—	3,332	3,357
Weighted average shares, diluted‡ thousands of shares	755	—	1,089	1,111	1,112	1,142*	1,257	1,444	2,051	—	3,905	3,357

‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (June 2026); filings made before it reported them unadjusted.

Balance sheet

CSV

Fiscal quarters (FEMY's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	8,692	21,716	17,836	13,526	7,611	3,452	3,820	3,218	4,569	9,266	5,386	1,444
Accounts receivable	104	99	121	93	378	488	234	255	572	617	172	151
Inventory	603	667	971	1,316	1,938	3,046	3,862	5,233	5,784	5,740	6,105	6,191
Total current assets	10,225	23,178	19,883	15,932	11,298	8,022	9,132	9,751	12,247	16,456	12,343	8,332
Property and equipment, net	1,161	1,111	1,214	1,262	1,388	1,596	1,575	1,600	1,749	1,896	1,924	1,859
Right-of-use asset	—	2,380	—	—	—	1,806	1,673	1,545	1,419	1,297	1,179	1,064
Total assets	14,854	27,756	24,371	20,276	15,585	12,445	13,278	13,780	16,290	20,724	16,495	12,290
Accounts payable	852	1,138	1,096	952	1,122	1,419	2,332	3,264	2,174	1,830	1,598	2,337
Accrued liabilities	569	1,444	673	886	1,128	1,151	1,170	1,053	1,028	1,266	1,025	1,034
Total current liabilities	2,187	3,054	2,358	2,464	2,867	8,583	9,841	10,964	10,542	3,636	3,155	3,887
Lease liability, non-current	—	2,036	—	—	—	1,518	1,393	1,269	1,148	1,030	913	796
Total liabilities	4,410	9,403	8,763	9,026	9,615	10,141	11,281	12,273	11,734	14,855	9,205	8,259
Accumulated deficit	(103,971)	(108,382)	(111,981)	(116,666)	(122,075)	(127,198)	(133,095)	(137,681)	(141,876)	(145,826)	(144,980)	(149,449)
Total stockholders' equity	10,444	18,353	15,608	11,250	5,970	2,304	1,997	1,507	4,556	5,869	7,290	4,031
Total liabilities and equity	14,854	27,756	24,371	20,276	15,585	12,445	13,278	13,780	16,290	20,724	16,495	12,290
Common shares outstanding (cover page)‡ thousands of shares	1,082	1,105	1,111	1,112	1,145	1,357	1,362	1,629	2,924	3,020	3,020	8,375

‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (June 2026); filings made before it reported them unadjusted.

Cash flows

CSV

Fiscal quarters (FEMY's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(3,997)	(4,410)*	(3,600)	(4,685)	(5,409)	(5,124)*	(5,897)	(4,586)	(4,195)	(3,950)*	846	(4,469)
Stock-based compensation	504*	49*	78	104*	128*	134*	367	182*	175*	66*	152	211*
Net cash from operating activities	(2,856)*	(3,036)*	(4,568)	(4,327)*	(5,475)*	(5,075)*	(4,765)	(4,353)*	(5,387)*	(4,185)*	(4,144)	(3,936)*
Purchases of property and equipment	27*	45*	65	182*	408*	107*	97	94*	194*	140*	79	9*
Net cash from investing activities	(27)*	(45)*	(90)	(207)*	(440)*	(111)*	(97)	(97)*	(240)*	(197)*	(79)	(22)*
Proceeds from issuing common stock	0*	7,662*	802	220*	0*	1,003*	5,392	(882)*	—	—	—	—
Share repurchases	0*	230*	24	7*	0*	30*	162	—	—	—	—	—
Net cash from financing activities	870*	16,105*	778	224*	0*	1,026*	5,230	3,848*	6,978*	9,079*	342	15*

Compare with peers

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Femasys	1,444	332	(3,936)*	8.4M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
DarioHealth	6,634	not reported	(6,083)*	9.8M	2.3 quarters	Q2 FY26 10-QJun 30, 2026
Cerenome	2,366	411	(7,132)*	7.6M	1.2 quarters	Q2 FY26 10-QJun 30, 2026
electroCore	8,501	9,450	(3,518)*	9.0M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
QT Imaging Holdings	10,924	7,435	(4,837)*	14.6M	2.3 quarters	Q2 FY26 10-QJun 30, 2026
Nephros	4,697	6,017	681*	10.9M	—	Q2 FY26 10-QJun 30, 2026
RenovoRx	9,479	909	(2,867)*	45.1M	3.3 quarters	Q2 FY26 10-QJun 30, 2026
Precision Optics	9,841	8,774*	(649)*	11.0M	15.2 quarters	Q4 FY26 10-KJun 30, 2026
Neuroone Medical Technologies	2,048	1,973	(1,082)*	9.1M	1.9 quarters	Q3 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.